克服 HER2+ 乳腺癌脑转移中的脑衍生的治疗阻力
Danyyl Ippolitov1, Yi-Han Lin2, Jeremy Spence1
1Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Manitoba, Canada.
bioRxiv : the preprint server for biology
|March 26, 2024
概括
开发了一种针对HER2+乳腺癌大脑转移 (BCBM) 的新型患者衍生模型. 穿透大脑的药物Poziotinib有效地消除了小鼠中的BCBM,与Lapatinib不同.
科学领域:
- 在瘤学瘤学.
- 神经瘤学神经瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- HER2+乳腺癌大脑转移 (BCBM) 的预后不好.
- 目前针对HER2的治疗方法对大脑的透程度有限,阻碍了BCBM治疗.
- 缺乏患者衍生的体外模型阻碍了BCBM研究.
结论:
- 建立了HER2+ BCBM的新型患者衍生体内模型.
- 鉴定Poziotinib作为一个高效的RTKi治疗HER2+BCBM由于其大脑透性.
- 波齐奥提尼布显示出对HER2+ BCBM的显著治疗潜力.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


